Boston Scientific (BSX) Reports In-Line Q3 EPS; Modestly Lifts Outlook

Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2.07 billion.

GUIDANCE:

Boston Scientific sees Q4 2016 EPS of $0.27-$0.29, versus the consensus of $0.27. Boston Scientific sees Q4 2016 revenue of $2.14-2.19 billion, versus the consensus of $2.15 billion.

Boston Scientific sees FY2016 EPS of $1.09-$1.11, versus prior guidance of $1.07-$1.00 and the consensus of $1.10. Boston Scientific sees FY2016 revenue of $8.335-8.385 billion, versus prior guidance of $8.27-8.37 billion and the consensus of $8.31 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• U.S. economy adds 199,000 jobs in November
• Guidewire Software (GWRE) Tops Q1 EPS by 16c, provides outlook
• Virco Mfg. Corp. (VIRC) Tops Q3 EPS by 23c